Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis.
Burman
W J
WJ
Denver Metro Tuberculosis Clinic, Denver Public Health, the Department of Medicine, University of Colorado Health Sciences Center, 80204, USA. bburman@dhha.org
Gallicano
K
K
Peloquin
C
C
D019380:Anti-HIV Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000904:Antibiotics, Antitubercular / Q000493:pharmacokinetics / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D004347:Drug Interactions; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D017320:HIV Protease Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D018894:Reverse Transcriptase Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use; D012294:Rifamycins / Q000493:pharmacokinetics* / Q000627:therapeutic use; D014376:Tuberculosis / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism
D019380:Anti-HIV Agents; D000904:Antibiotics, Antitubercular; D000995:Antitubercular Agents; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D012294:Rifamycins